Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

Lignende værker

• Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
  af: Retout, Sylvie, et al.
  Udgivet: (2020)
• Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
  af: Schmitt, Christophe, et al.
  Udgivet: (2021)
• Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis
  af: Fabius J. Pelzer, et al.
  Udgivet: (2025-11-01)
• Real world data of emicizumab prophylaxis in young children with severe hemophilia a without inhibitors
  af: Sanjeev Khera, et al.
  Udgivet: (2025-01-01)
• Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
  af: Callaghan, Michael U., et al.
  Udgivet: (2021)